221 related articles for article (PubMed ID: 34356836)
1. T2-High Endotype and Response to Biological Treatments in Patients with
Oriano M; Gramegna A; Amati F; D'Adda A; Gaffuri M; Contoli M; Bindo F; Simonetta E; Di Francesco C; Santambrogio M; Sotgiu G; Blasi F; Aliberti S
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356836
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis.
Chen F; Zeng Z; Huang X; Liu Y
Chron Respir Dis; 2023; 20():14799731231210559. PubMed ID: 37889184
[TBL] [Abstract][Full Text] [Related]
3. Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?
Carpagnano GE; Scioscia G; Lacedonia D; Soccio P; Lepore G; Saetta M; Foschino Barbaro MP; Barnes PJ
Chest; 2018 Nov; 154(5):1083-1090. PubMed ID: 30336944
[TBL] [Abstract][Full Text] [Related]
4. Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.
Pelletier G; Godbout K; Boulay MÈ; Boulet LP; Morissette MC; Côté A
J Asthma Allergy; 2022; 15():691-701. PubMed ID: 35615256
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era.
Jackson DJ; Busby J; Pfeffer PE; Menzies-Gow A; Brown T; Gore R; Doherty M; Mansur AH; Message S; Niven R; Patel M; Heaney LG;
Thorax; 2021 Mar; 76(3):220-227. PubMed ID: 33298582
[TBL] [Abstract][Full Text] [Related]
6. Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study.
Chen YF; Hou HH; Chien N; Lu KZ; Chen YY; Hung ZC; Chien JY; Wang HC; Yu CJ
Lung; 2024 Jun; ():. PubMed ID: 38884647
[TBL] [Abstract][Full Text] [Related]
7. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab.
Carpagnano GE; Scioscia G; Lacedonia D; Curradi G; Foschino Barbaro MP
J Asthma Allergy; 2019; 12():83-90. PubMed ID: 30881051
[TBL] [Abstract][Full Text] [Related]
8. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis.
Petsky HL; Cates CJ; Kew KM; Chang AB
Thorax; 2018 Dec; 73(12):1110-1119. PubMed ID: 29858277
[TBL] [Abstract][Full Text] [Related]
9. Impact of asthma on bronchiectasis severity and risk of exacerbations.
Ferri S; Crimi C; Campisi R; Cacopardo G; Paoletti G; Puggioni F; Crimi N; Heffler E
J Asthma; 2022 Mar; 59(3):469-475. PubMed ID: 33256490
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilic Endotype of Asthma.
Aleman F; Lim HF; Nair P
Immunol Allergy Clin North Am; 2016 Aug; 36(3):559-68. PubMed ID: 27401626
[TBL] [Abstract][Full Text] [Related]
11. T2-high Asthma, Classified by Sputum mRNA Expression of
Rijavec M; Krumpestar T; Škrgat S; Kern I; Korošec P
Life (Basel); 2021 Jan; 11(2):. PubMed ID: 33513844
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
13. Biologics in asthma management - Are we out of breath yet?
Struß N; Hohlfeld JM
Allergol Select; 2021; 5():96-102. PubMed ID: 33615123
[TBL] [Abstract][Full Text] [Related]
14. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.
Tsikrika S; Dimakou K; Papaioannou AI; Hillas G; Thanos L; Kostikas K; Loukides S; Papiris S; Koulouris N; Bakakos P
Cytokine; 2017 Nov; 99():281-286. PubMed ID: 28863927
[TBL] [Abstract][Full Text] [Related]
15. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional Assessment of Asthma Identifies Clinically Relevant Phenotype Overlap: A Cross-Sectional Study.
Han YY; Zhang X; Wang J; Wang G; Oliver BG; Zhang HP; Kang Y; Wang L; Qiu ZX; Li WM; Wang G
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):349-362.e18. PubMed ID: 32791248
[TBL] [Abstract][Full Text] [Related]
17. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma.
Soma T; Iemura H; Naito E; Miyauchi S; Uchida Y; Nakagome K; Nagata M
Allergol Int; 2018 Sep; 67S():S3-S11. PubMed ID: 29754974
[TBL] [Abstract][Full Text] [Related]
18. Bronchiectasis in severe asthma and asthmatic components in bronchiectasis.
Matsumoto H
Respir Investig; 2022 Mar; 60(2):187-196. PubMed ID: 34924307
[TBL] [Abstract][Full Text] [Related]
19. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
[Next] [New Search]
